Stockreport

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF -Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD--Initiation of Phase 3 program remains on schedule to begin in second half of [Read more]